We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Kenvue's Q3 Earnings on the Horizon: Key Insights for Investors
Read MoreHide Full Article
Key Takeaways
KVUE likely benefited from stronger brand investments, e-commerce expansion and favorable pricing.
KVUE's Self Care growth likely gained support from Zyrtec, Pepcid, Tylenol and Nicorette demand.
KVUE's cost-saving initiatives likely supported efficiency, but inflation likely weighed on margins.
As Kenvue Inc. (KVUE - Free Report) prepares to unveil its third-quarter fiscal 2026 results on Oct. 30, before market open, investors are eager to see whether the company can beat market expectations.
The Zacks Consensus Estimate for revenues is pegged at $3.9 billion, implying 3.3% growth from the prior year. Meanwhile, the consensus mark for earnings has remained unchanged at 28 cents per share in the past seven days and implies flat year-over-year. KVUE has an average trailing four-quarter earnings surprise of 10.5%.
Key Factors to Observe for KVUE's Q3 Earnings
Kenvue's performance is likely to have benefited from improving organic sales trends, brand-building initiatives and product innovation in the third quarter of 2026. The company has been witnessing encouraging momentum across its consumer health portfolio, supported by stronger commercial execution and expanding e-commerce capabilities. Continued investments in core brands, improved market penetration and favorable pricing across select categories are likely to have supported quarterly performance.
Kenvue's Self Care segment is likely to have gained from improving demand for allergy, digestive health and pain relief products. Strong execution behind Zyrtec and Pepcid, along with improving consumption trends for Tylenol, might have supported sales. The company's smoking cessation portfolio, particularly Nicorette, has also been witnessing healthy momentum across international markets. However, softer category demand and uneven consumer purchasing patterns might have limited volume growth.
On the profitability front, Kenvue's ongoing supply-chain optimization and cost-saving initiatives under Our Vue Forward and its 2026 restructuring program are likely to have supported operating efficiencies. Improved productivity and disciplined cost management might have provided some relief.
Nevertheless, inflationary pressures, tariffs, unfavorable transactional currency movements and increased brand-support spending are likely to have weighed on margins. Heightened competition and cautious consumer spending might also have affected the quarter's overall performance.
What the Zacks Model Says About KVUE
Our proven model does not conclusively predict an earnings beat for KVUE this time. The combination of a positive Earnings ESP and a Zacks Rank #1 (Strong Buy), 2 (Buy) or 3 (Hold) increases the odds of an earnings beat, which is not the case here.
KVUE has an Earnings ESP of 0.00% and a Zacks Rank #4 (Sell). You can uncover the best stocks to buy or sell before they’re reported with our Earnings ESP Filter.
Stocks With Favorable Combination
Here are three companies you may also want to consider, as our model shows that these have the right combination of elements to post an earnings beat this season:
BJ’s Wholesale Club Holdings, Inc. (BJ - Free Report) has an Earnings ESP of +2.54% and currently carries a Zacks Rank of 2. The Zacks Consensus Estimate for third-quarter fiscal 2026 earnings per share is pegged at 1.22 cents, implying 5.2% year-over-year growth. You can see the complete list of today’s Zacks #1 Rank stocks here.
The Zacks Consensus Estimate for quarterly revenues is pegged at $5.6 billion, which indicates an increase of 6.2% from the figure reported in the prior-year quarter. BJ has a trailing four-quarter earnings surprise of 11.1%, on average.
Colgate-Palmolive Company (CL - Free Report) has an Earnings ESP of +0.01% and currently carries a Zacks Rank of 3. The Zacks Consensus Estimate for third-quarter fiscal 2025 earnings per share is pegged at 92 cents, implying 1.1% year-over-year growth.
The Zacks Consensus Estimate for quarterly revenues is pegged at $5.3 billion, which indicates an increase of 3.9% from the figure reported in the prior-year quarter. CL has a trailing four-quarter earnings surprise of 3.2%, on average.
Church & Dwight Co., Inc. (CHD - Free Report) currently has an Earnings ESP of +0.06% and a Zacks Rank of 3. The Zacks Consensus Estimate for third-quarter fiscal 2027 earnings per share is pegged at 90 cents, implying an 11% year-over-year increase.
The Zacks Consensus Estimate for quarterly revenues is pegged at $1.6 billion, which indicates a decline of 0.2% from the figure reported in the prior-year quarter. CHD has a trailing four-quarter earnings surprise of 1%, on average.
View the Zacks #1 Rank List
Image: Bigstock
Kenvue's Q3 Earnings on the Horizon: Key Insights for Investors
Key Takeaways
As Kenvue Inc. (KVUE - Free Report) prepares to unveil its third-quarter fiscal 2026 results on Oct. 30, before market open, investors are eager to see whether the company can beat market expectations.
The Zacks Consensus Estimate for revenues is pegged at $3.9 billion, implying 3.3% growth from the prior year. Meanwhile, the consensus mark for earnings has remained unchanged at 28 cents per share in the past seven days and implies flat year-over-year. KVUE has an average trailing four-quarter earnings surprise of 10.5%.
Key Factors to Observe for KVUE's Q3 Earnings
Kenvue's performance is likely to have benefited from improving organic sales trends, brand-building initiatives and product innovation in the third quarter of 2026. The company has been witnessing encouraging momentum across its consumer health portfolio, supported by stronger commercial execution and expanding e-commerce capabilities. Continued investments in core brands, improved market penetration and favorable pricing across select categories are likely to have supported quarterly performance.
Kenvue's Self Care segment is likely to have gained from improving demand for allergy, digestive health and pain relief products. Strong execution behind Zyrtec and Pepcid, along with improving consumption trends for Tylenol, might have supported sales. The company's smoking cessation portfolio, particularly Nicorette, has also been witnessing healthy momentum across international markets. However, softer category demand and uneven consumer purchasing patterns might have limited volume growth.
On the profitability front, Kenvue's ongoing supply-chain optimization and cost-saving initiatives under Our Vue Forward and its 2026 restructuring program are likely to have supported operating efficiencies. Improved productivity and disciplined cost management might have provided some relief.
Nevertheless, inflationary pressures, tariffs, unfavorable transactional currency movements and increased brand-support spending are likely to have weighed on margins. Heightened competition and cautious consumer spending might also have affected the quarter's overall performance.
What the Zacks Model Says About KVUE
Our proven model does not conclusively predict an earnings beat for KVUE this time. The combination of a positive Earnings ESP and a Zacks Rank #1 (Strong Buy), 2 (Buy) or 3 (Hold) increases the odds of an earnings beat, which is not the case here.
KVUE has an Earnings ESP of 0.00% and a Zacks Rank #4 (Sell). You can uncover the best stocks to buy or sell before they’re reported with our Earnings ESP Filter.
Stocks With Favorable Combination
Here are three companies you may also want to consider, as our model shows that these have the right combination of elements to post an earnings beat this season:
BJ’s Wholesale Club Holdings, Inc. (BJ - Free Report) has an Earnings ESP of +2.54% and currently carries a Zacks Rank of 2. The Zacks Consensus Estimate for third-quarter fiscal 2026 earnings per share is pegged at 1.22 cents, implying 5.2% year-over-year growth. You can see the complete list of today’s Zacks #1 Rank stocks here.
The Zacks Consensus Estimate for quarterly revenues is pegged at $5.6 billion, which indicates an increase of 6.2% from the figure reported in the prior-year quarter. BJ has a trailing four-quarter earnings surprise of 11.1%, on average.
Colgate-Palmolive Company (CL - Free Report) has an Earnings ESP of +0.01% and currently carries a Zacks Rank of 3. The Zacks Consensus Estimate for third-quarter fiscal 2025 earnings per share is pegged at 92 cents, implying 1.1% year-over-year growth.
The Zacks Consensus Estimate for quarterly revenues is pegged at $5.3 billion, which indicates an increase of 3.9% from the figure reported in the prior-year quarter. CL has a trailing four-quarter earnings surprise of 3.2%, on average.
Church & Dwight Co., Inc. (CHD - Free Report) currently has an Earnings ESP of +0.06% and a Zacks Rank of 3. The Zacks Consensus Estimate for third-quarter fiscal 2027 earnings per share is pegged at 90 cents, implying an 11% year-over-year increase.
The Zacks Consensus Estimate for quarterly revenues is pegged at $1.6 billion, which indicates a decline of 0.2% from the figure reported in the prior-year quarter. CHD has a trailing four-quarter earnings surprise of 1%, on average.